Re-examination of the lymphocytotoxic crossmatch in liver transplantation: Can C4d stains help in monitoring?

American Journal of Transplantation

Volumn 12, Issue 1, 2012, Pages 171-182

  Lunz, J ^a   Ruppert, K M ^b   Cajaiba, M M ^a   Isse, K ^a   Bentlejewski, C A ^a   Minervini, M ^a   Nalesnik, M A ^a   Randhawa, P ^a   Rubin, E ^a   Sasatomi, E ^a   Vera, M E De ^c   Fontes, P ^a   Humar, A ^a   Zeevi, A ^a   Demetris, A J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

Author keywords

Allograft monitoring; antibody mediated rejection; complement C4d; crossmatching; liver allograft

Indexed keywords

COMPLEMENT COMPONENT C4D;

ADOLESCENT; ADULT; AGED; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP TYPING; CHILD; CORRELATION ANALYSIS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER INJURY; LIVER TRANSPLANTATION; LYMPHOCYTOTOXICITY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROLOGY; STAINING; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; COMPLEMENT C4B; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 84855923061     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03786.x     Document Type: Article

References (39)

1. Demetris AJ, Jaffe R, Tzakis A, et al,. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988; 132: 489-502.
2. Demetris AJ, Nakamura K, Yagihashi A, et al,. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671-681.
3. Knechtle SJ, Kolbeck P, Tsuchimoto S, Sanfilippo F, Bollinger RR,. Hyperacute rejection of liver transplants in rats. Curr Surg 1986; 43: 303-305.
4. Kakizoe S, Yanaga K, Starzl TE, Demetris AJ,. Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: Considerations of preservation and early immunological injury. Hepatology 1990; 11: 932-941. (Pubitemid 20221027)
5. Batts KP, Moore SB, Perkins JD, Wiesner RH, Grambsch PM, Krom RA,. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988; 45: 376-379. (Pubitemid 18084679)
6. Demetris AJ, Murase N, Nakamura K, et al,. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. [Review]. Semin Liver Dis 1992; 12: 51-59.
7. Musat AI, Agni RM, Wai PY, et al,. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
8. Nakamura K, Murase N, Becich MJ, et al,. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993; 142: 1383-1391. (Pubitemid 24058125)
9. Furuya T, Murase N, Nakamura K, et al,. Preformed lymphocytotoxic antibodies: The effects of class, titer and specificity on liver vs. heart allografts. Hepatology 1992; 16: 1415-1422.
10. Kozlowski T, Rubinas T, Nickeleit V, et al,. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl. 2011; 17: 357-368.
11. Feucht HE, Schneeberger H, Hillebrand G, et al,. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338. (Pubitemid 23161421)
12. Colvin RB,. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046-1056. (Pubitemid 46536891)
13. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ,. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007; 50: 739-749. (Pubitemid 46683930)
14. Bu X, Zheng Z, Yu Y, Zeng L, Jiang Y,. Significance of C4d deposition in the diagnosis of rejection after liver transplantation. Transplant Proc 2006; 38: 1418-1421.
15. Dankof A, Schmeding M, Morawietz L, et al,. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch 2005; 447: 87-93. (Pubitemid 41126244)
16. Haga H, Egawa H, Fujimoto Y, et al,. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006; 12: 457-464.
17. Jain A, Mohanka R, Orloff M, et al,. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin Transplant 2006; 20: 624-633. (Pubitemid 44383409)
18. Krukemeyer MG, Moeller J, Morawietz L, et al,. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78: 65-70.
19. Sakashita H, Haga H, Ashihara E, et al,. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007; 20: 676-684. (Pubitemid 46788874)
20. Sawada T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S,. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant 2005; 19: 110-114. (Pubitemid 40227861)
21. Troxell ML, Higgins JP, Kambham N,. Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006; 130: 1489-1496. (Pubitemid 44520715)
22. Martelius T, Halme L, Arola J, Hockerstedt K, Lautenschlager I,. Vascular deposition of complement C4d is increased in liver allografts with chronic rejection. Transpl Immunol 2009; 21: 244-246.
23. Bouron-Dal Soglio D, Rougemont AL, Herzog D, Soucy G, Alvarez F, Fournet JC,. An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases. Hum Pathol 2008; 39: 1103-1110. (Pubitemid 351822384)
24. Manez R, Kelly RH, Kobayashi M, et al,. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: Studies toward further defining their significance. Hepatology 1995; 21: 1345-1352.
25. Bathgate AJ, McColl M, Garden OJ, Forsythe JL, Madhavan KK, Hayes PC,. The effect of a positive T-lymphocytotoxic crossmatch on hepatic allograft survival and rejection. Liver Transpl Surg 1998; 4: 280-284. (Pubitemid 28323747)
26. Suehiro T, Shimada M, Kishikawa K, et al,. Influence of HLA compatibility and lymphocyte cross-matching on acute cellular rejection following living donor adult liver transplantation. Liver Int 2005; 25: 1182-1188. (Pubitemid 41782563)
27. DiMartini A, Chopra K,. The importance of hepatic encephalopathy: Pre-transplant and post-transplant. Liver Transpl 2009; 15: 121-123.
28. Eghtesad B, Fung JJ, Demetris AJ, et al,. Immunosuppression for liver transplantation in HCV-infected patients: Mechanism-based principles. Liver Transpl 2005; 11: 1343-1352. (Pubitemid 43071583)
29. Takaya S, Bronsther O, Iwaki Y, et al,. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53: 400-406.
30. Muro M, Marin L, Miras M, et al,. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: Experience of one centre. Transpl Immunol 2005; 14: 91-97. (Pubitemid 40791124)
31. Castillo-Rama M, Castro MJ, Bernardo I, et al,. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562. (Pubitemid 351524413)
32. Watson R, Kozlowski T, Nickeleit V, et al,. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022-3029.
33. Takemoto SK, Zeevi A, Feng S, et al,. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041. (Pubitemid 38868592)
34. Nickeleit V, Mihatsch MJ,. Kidney transplants, antibodies and rejection: Is C4d a magic marker? Nephrol Dial Transplant 2003; 18: 2232-2239. (Pubitemid 37336808)
35. Glanville AR,. Antibody-mediated rejection in lung transplantation: Myth or reality? J Heart Lung Transplant; 29: 395-400.
36. Girnita A, Mazariegos GV, Castellaneta A, et al,. Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum Immunol 2009.; 71: 274-276.
37. Feng S, Ekong U, Lobritto S, et al,. Clinical and histological predictors of operational tolerance in pediatric liver transplant recipients. Am J Transplant 2011; 11: 152.
38. Rensen SS, Slaats Y, Driessen A, et al,. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 2009; 50: 1809-1817.
39. Ali SA, Shah V, McKinnon R, Van Harn M, Janakiraman N,. Frequent expression of C4d in hepatic graft-versus-host disease: Potential clue for diagnosis and distinguishing acute and chronic form. Transpl Immunol; 23: 77-80.